Hemab Therapeutics, a Phase 3-ready biotech developing blood coagulation disorder treatments, filed on Friday with the SEC to raise up to $100 million in an initial public offering.Hemab is a clinical-stage biotechnology company developing antibody-based therapies for inherited bleeding and ... Hemab Therapeutics, a Phase 3-ready biotech developing blood coagulation disorder treatments, filed on Friday with the SEC to raise up to $100 million in an initial public offering.Hemab is a clinical-stage biotechnology company developing antibody-based therapies for inherited bleeding and coagulat... Hemab is a clinical-stage biotechnology company developing antibody-based therapies for inherited bleeding and coagulation disorders. Its lead candidate, sutacimig (HMB-001), finished Phase 2 and is ready for Phase 3 for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency, while HMB-002 is in Phase 1/2 for Von Willebrand Disease. The company’s programs are focused on prophylactic subcutaneous treatments for rare disorders with limited existing options, and it is also advancing additional preclinical candidates in coagulation-related diseases.

Original title: “COAG IPO News - Coagulation disorder biotech Hemab Therapeutics files for a $100 million IPO”